Biologics will be the fastest growing sector of the pharmaceutical industry in the next decade. Nearly 30 to 40% of medical drugs will be made in the biopharmaceutical production process. This will certainly lead to a high level demand for pharmacuetical industry resources and create bottlenecks. How will your company prepare to get the right people on board for this growing sector? What skill sets and capabilities are needed in the future? How can companies work with academia to ensure upcoming pharmaceutical young professionals have the right foundation? Biologics are complex and require a high level of specialisation, which leads to the need for developing networks of big and small companies who can work together on similar projects. Management capabilities, such as project management and setting up supply and quality agreements, will also be needed now, more than ever before. Join top pharmaceutical industry professionals and NIBRT, the National Institute for Bioresearch and Technology, as they address these questions and more at the ISPE 2017 Europe Biotechnology Conference in Dublin 26 – 27 September 2017. The ISPE 2017 Europe Biotechnology Conference will highlight case studies and address the specific challenges and opportunities in managing technical projects related to the five megatrends in biotechnology which include:
Network with peers, key pharmaceutical industry suppliers, and Young Professionals to get the answers you need to stay ahead of the fastest growing sector of the pharmaceutical industry at the ISPE 2017 Europe Biotechnology Conference.
Looking forward to seeing you in Dublin in September!
Through the ISPE Foundation Professional Development Grant program, Silas Tamufor attended the 2023 ISPE Annual Meeting & Expo in October 2023. Tamufor is a PhD student and ISPE Boston Chapter member who began serving as the ISPE Boston Educational Programs Committee Chair in December 2023. He, along with 87 other students and recent graduates, attended the conference thanks to the...
To meet the biopharmaceutical industry’s duty to manufacture safe and effective therapies for patients, a robust quality system is fundamental to success. A quality system should link to quality culture and prioritize focusing on quality, led by management, that fosters sustainable compliance and consistent production of high-quality drugs. Strong quality culture attributes include a proactive...
Stability sampling and testing are key to ensuring that products maintain safety, identity, strength, purity, and quality throughout their claimed shelf life. It is also a regulatory requirement per ICH Q5. However, storing product samples in different environmental conditions, testing those samples for three to five years (or more) after initial manufacture, and properly analyzing and...